Exploration of the optimized parameters for bioactive prodigiosin mass production and its biomedical applications in vitro as well as in silico

Prodigiosin from Serratia marcescens is considered as an important secondary metabolite for various significant applications. This study explores the optimized conditions for the maximal prodigiosin production, characterization of prodigiosin, and biomedical applications against therapeutically important diseases. Prodigiosin was extracted, purified using different solvents and the purified prodigiosin was characterized using FT-IR, UV-Vis Spectrometry and GC-MS analysis respectively. UV-Vis spectrophotometry showed the absorbance peak at 530 nm and the FT-IR result revealed that prodigiosin contains most of the functional groups that are corresponding to the literature reports and also GC -MS analysis validated the presence of prodigiosin by showing the peak at 323 m/z. Antibacterial activity showed a higher activity against Staphylococcus sp. than Gram negative bacteria and showed a very effective activity against Candida sp. than other tested fungi. The larvicidal activity of prodigiosin against Aedes aegypti clearly indicated that 32 % and 76 % mortality rate was seen at 24 and 48 h respectively. In silico analysis of prodigiosin against A beta peptide 1-42, a well-known breast cancer protein RAF-1 and two viral proteins El A and TMV-CP revealed that it has a strong interaction with less binding energy. Altogether, it is strongly endorsed that the prodigiosin pigment could pave a way to treat various bacterial infections and disorders in the forthcoming existences.